| INTRODUCTION
Atopic dermatitis (AD) is a common, chronic or chronically relapsing, severely pruritic, eczematous skin disease that markedly deteriorates quality of life of the afflicted patients. [1] [2] [3] [4] Clinical symptoms and signs of AD are characterized by skin inflammation, xerosis, and itching. 1, 5, 6 Severe pruritus induces sleep disturbance in AD patients and their caregivers. [7] [8] [9] The itch-sleepless circuit may increase attentiondeficit/hyperactivity disorder in children as well as in adults with AD. 8, 9 Their stress levels are also very high. 10 Atopic dermatitis is more frequent in childhood, especially in the first five years of life. 11, 12 The prevalence or incidence of AD in the first five years of childhood is 10%-16.5% and is generally considered to be increasing worldwide, at least from the 1980s to early 2000s. [13] [14] [15] Most pediatric AD cases are mild-to-moderate in severity, with 84% of cases considered mild, 14% moderate, and only 2%
severe. 13 The number of patients with adult AD (over 40 years of age) has decreased rapidly, 14, 16 but the occurrence of AD in senile or elderly patients is also currently an important issue.
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Atopic dermatitis is composed of heterogeneous pathophysiological groups regarding onset, persistence, genetics, seasonality, and IgE sensitization. 1, 2, 11, [18] [19] [20] [21] Eighty percent of childhood AD does not persist past eight years, but most patients remit by adulthood. 11, 22, 23 Less than 5% of childhood AD persists for 20 years after diagnosis.
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Moreover, children who developed AD in the first two years of life have significantly lower risk of persistent disease than those who developed AD later in childhood or adolescence. 11 Children with moderate-to-severe AD at age 9-16 months are more likely to have persistent AD 6-12 years later compared to those with mild disease. 24 Fifty percent of subjects have at least one six-month symptom-/treatment-free period, but symptoms frequently recur until 20 years of age. 25 Therefore, AD is a lifelong illness.
strongest risk factors are null mutations of FLG gene, resulting in epidermal barrier deficiency. 18, 27 In accordance, FLG expression levels have been reported to be reduced in lesional and nonlesional skin in AD patients. [28] [29] [30] Ichthyosis vulgaris is also known to be caused by a loss-of-function mutation of the FLG gene. 31 This may explain why AD is significantly comorbid with ichthyosis vulgaris. 32, 33 Children with FLG mutations were more likely to have persistent AD. 25 However, FLG mutations are not found in all AD patients, and they are less common in southern Europeans 34 and are even absent in some African countries. 35, 36 A humid atmosphere may reduce the contribution of FLG mutations to the onset of AD.
37
These studies reiterate the genetic heterogeneity of AD.
| THDEVIATION IN ATOPIC DERMATITIS
Compiling evidence has shown that acute AD lesions have a significantly greater number of T helper 2 (Th2) cells expressing interleukin-4 (IL-4) and IL-13 compared with normal skin or unaffected AD skin ( Figure 1) . 38, 39 The Th2-deviated immune response is demonstrated both in pediatric and adult AD [40] [41] [42] and is more pronounced in chronic lesions than in acute lesions. 40, 43 In addition to The barrier dysfunction is associated with atopic dry skin, increased penetration of allergens, and enhanced Staphylococcus aureus colonization. 62 In line with this notion, topical steroids significantly improve clinical inflammatory signs and normalize transepidermal water loss in lesional AD skin because of the upregulation of FLG and LOR expression. 63 These improvements are associated with the downregulation of the Th2 signatures such as IL-13 and IL-31. 63 OVOL1 is an upstream transcription factor for FLG and LOR expression 29, 64 and is one of the susceptibility genes for AD. 18 IL-4 is known to inhibit the activation of OVOL1 by interfering with its cytoplasmic to nuclear translocation. 
| CHEMOKINE S IN ATOPIC DE RMATITIS
In parallel with the pivotal participation of Th2/Th22 cells, the upregulation of chemokines and chemokine receptors is also an integral component of atopic inflammation, that is, CCL1, CCL4, CCL13, CCL17, CCL18, CCL20, CCL22, CCL26, CXCL1, CXCL2, CXCL3, CXCL8, CXCL9, CXCL10, CCR1, and CCR7 ( Figure 1 ). [70] [71] [72] [73] Among them, CCL17, CCL22, and CCL26 are key Th2-related chemokines.
Serum levels of CCL17 and CCL22 are elevated in patients with AD compared to healthy controls and are associated with disease severity. [74] [75] [76] Topical steroids are effective in normalizing the levels of CCL17 and CCL22. 63, 77, 78 Notably, serum TARC levels are inversely correlated with corneal water content not only in mild AD patients but also in healthy controls. 79 Dendritic cells, especially Langerhans cells, are one of the major sources of CCL17 and CCL22 production upon IL-4 stimulation. [80] [81] [82] CCL17 and CCL22 are potent attractants for CCR4-expressing Th2 cells. 83, 84 Increased CCL17 is also evident in AD-like mouse models. 85 Normal pregnancy is associated with Th2 skewing of the immune system. This is most pronounced at the maternal-fetal interface and affords protection to the "semi-allogeneic" fetus. [86] [87] [88] This Th2 bias persists in the neonates and infants, and it is likely to promote onset of infantile atopic diseases such as AD and food allergies. 86, 89, 90 Consistent with this notion, the levels of CCL17 and CCL22 are highest in neonates and then decrease over the course of the following two years. [91] [92] [93] Umbilical cord blood CCL22 levels were positively associated with IgE sensitization at age 2. 94 Cord blood levels of CCL17 from neonates destined to develop AD in infancy are higher than those from neonates who show no signs of AD during infancy. Moreover, high umbilical cord serum levels of CCL17 are associated with infantile AD development in neonates born to mothers without AD. 95 Serum levels of CCL17 are higher in childhood AD patients with egg allergy than those without egg allergy. 73, 96 CCL26 is also a Th2-associated chemokine, which potently attracts eosinophils. 97 Levels of CCL26 are elevated in the sera and lesional skins of patients with AD and are correlated with their disease activity. 98 Notably, administration of dupilumab significantly diminishes the lesional expression of CCL26 as well as CCL17 and CCL22 in AD. 99 Cord blood IgE levels are apparently associated with onset of food allergies in infants. 109 IgE levels specific for ovomucoid, wheat, and mite allergens are correlated with serum levels of the Th2-related chemokines CCL17 and CCL22 in childhood AD. 71, 73, 110 The skin barrier dysfunction with FLG mutation and increased S. aureus colonization contribute to disease progression and aberrant IgE production in AD. cantly improves atopic inflammation. 45, 114 In addition, the anti-IL-31 receptor A antibody nemolizumab successfully resolves atopic itch. 57, 115 Despite the safety and the considerable effectiveness of these biologics, there still exists high and low responders. This fact reiterates the heterogeneity of AD. Search for relevant biomarkers that dictate treatment response is warranted for these targeted biologic therapies.
| IGE IN ATOPIC DERMATITIS
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